DiabeCell: Interim Phase II data

Interim data from 4 patients in an ongoing, dose-ranging, New Zealand Phase II trial showed that 1 DiabeCell implant of 10,000 islet equivalents/kg reduced the severity of hypoglycemic events by 64% a...